| [1] |
Rosa M. Advances in the molecular analysis of breast cancer: pathway toward personalized medicine[J]. Cancer Control, 2015, 22(2): 211-219.
|
| [2] |
Padmanabhan N, Rubens RD, Howell A. Adjuvant chemotherapy in early breast cancer[J]. Lancet, 1986, 2(8519): 1333-1334.
|
| [3] |
Winer EP. Optimizing endocrine therapy for breast cancer[J]. J Clin Oncol, 2005, 23(8): 1609-1610.
|
| [4] |
Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview[J]. BMC Med, 2015, 13: 195.
|
| [5] |
Incorvati JA, Shah S, Mu Y, et al. Targeted therapy for HER2 positive breast cancer[J]. J Hematol Oncol, 2013, 6: 38.
|
| [6] |
Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J]. J Clin Oncol, 1999, 17(5): 1474-1481.
|
| [7] |
Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials[J]. Lancet, 2011, 378(9793): 771-784.
|
| [8] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 365(9472): 1687-1717.
|
| [9] |
Petrelli F, Coinu A, Cabiddu M, et al. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials[J]. Breast Cancer Res Treat, 2013, 140(2): 233-240.
|
| [10] |
Al-Mubarak M, Tibau A, Templeton AJ, et al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis[J]. PLoS One, 2014, 9(2): e88238.
|
| [11] |
Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group[J]. J Natl Cancer Inst, 1996, 88(24): 1828-1833.
|
| [12] |
Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group[J]. Br J Cancer, 1996, 74(2): 297-299.
|
| [13] |
Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial[J]. J Natl Cancer Inst, 2001, 93(9): 684-690.
|
| [14] |
Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a[J]. J Natl Cancer Inst, 2007, 99(24): 1845-1853.
|
| [15] |
Ingle JN, Tu D, Pater JL, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17[J]. Ann Oncol, 2008, 19(5): 877-882.
|
| [16] |
Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial[J]. J Clin Oncol, 2008, 26(12): 1965-1971.
|
| [17] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
|
| [18] |
Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6, 953 women with early breast cancer [EB/OL]. [2017-03-16].
URL
|
| [19] |
Mamounas EP, Bandos H, Lembersky BC, et al. A randomized, double-blinded, placebocontrolled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormonereceptor (＋) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG oncology/NSABP B-42. [EB/OL]. [2017-03-16].
URL
|
| [20] |
Tjan-Heijnen V, Hellemond IV, Peer P, et al. First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifenin postmenopausal women with hormone receptor-positive early breast cancer[EB/OL]. [2017-03-16].
URL
|
| [21] |
Zdenkowski N, Forbes JF, Boyle FM, et al. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial[J]. Ann Oncol, 2016, 27(5): 806-812.
|
| [22] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [23] |
Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence[J]. Clin Cancer Res, 2013, 19(15): 4196-4205.
|
| [24] |
Higgins MJ, Liedke PE, Goss PE. Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial[J]. Crit Rev Oncol Hematol, 2013, 86(1): 23-32.
|